"Innovative Viral Vector Manufacturing and Technologies Drive Breakthroughs in Advanced Vaccines and Gene Therapies, Tackling ...

The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.

Demand for adeno-associated viral (AAV) vectors is increasing as more and more cell and gene therapy firms use them to make products. In response, vector suppliers are embracing faster, more efficient ...

Rising demand for gene and cell therapies, expanding mRNA vaccine pipelines, and increasing investments in GMP-compliant manufacturing facilities are driving growth in the viral vectors and plasmid ...

Authors explore complexities in scaling gene-therapy production with special attention is to monitoring and enhancing ...

Bristol Myers Squibb’s cancer cell therapy Breyanzi. Johnson & Johnson and AstraZeneca’s recombinant COVID-19 vaccines. Novartis’ gene therapy Zolgensma. All of these, plus many others, are united by ...

Merck KGaA and subsidiary MilliporeSigma are doubling down on their gene therapy bets with a hefty nine-figure investment into expanded viral vector production. MilliporeSigma will spend $110 million ...

Vector Biolabs, a custom design and manufacturing service provider for AAV and adenovirus viral vectors announced the completion of a facility expansion to meet growing demand. The purpose of the ...

Viral vectors are indispensable tools for advancing gene therapy discovery and development. As researchers progress towards clinically relevant processes, scaling up production and clarification of ...

The popularity of viral vector-based gene therapies and vaccines is rapidly growing. However, it is often difficult for scientists to ramp up the generation of these vectors to meet their needs at ...

SAN FRANCISCO & COLUMBUS, Ohio--(BUSINESS WIRE)--Ray Therapeutics, a biotechnology company developing optogenetic gene therapies for patients with retinal degenerative conditions, and Forge Biologics, ...

BOSTON & SEATTLE & COLUMBUS, Ohio--(BUSINESS WIRE)--GentiBio, Inc., an emerging biotherapeutics company developing best-in-class engineered regulatory T cells programmed to treat autoimmune, ...